Skip to content
‹ Back to IndustriesHealthcare

Barrow Hanley Credit Partners: Lens on Credit Series | Credit Markets: Then vs. Now

Credit Markets: Then vs. Now Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies. More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Credit Markets: Then vs. Now

Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies.

More about Chet Paipanandiker, Portfolio Manager

More about Nick Losey, Portfolio Manager

Video TranscriptExpand ↓

Yes the credit markets have been in a pretty interesting place over the last three years. We've basically been through a mini credit cycle. If you think back to what happened, go back to the early part of 2020, basically at a global pandemic. And by virtue of the Fed stepping in and helping to solve capital markets as well as work to develop a vaccine, we actually saw a credit markets do a complete about face. We started out with companies contemplating zero revenues and by the latter part of the year with the benefit of a vaccine, as well as with the benefit of companies terming out maturities and raising cash, basically enhancing their liquidity. You saw revenues come back and you saw companies with pretty pumped up liquidity facilities. So as a result, they were able to better handle the stresses that were occurring at the time, whether it's because of revenues, labor availability or inflation. At the same time, something else was happening to the consumer. You basically saw the consumer also see its balance sheet get pumped up by virtue of the stimulus checks that came through. And so pretty much you went through this period of extreme volatility where companies and consumers were in a bad place. They basically didn't about ship and everyone ended up in a generally better place from a fundamental perspective. And so what did that do with credit markets? We certainly saw a swoon to the downside when COVID occurred. Credit markets rebounded. As you went to the earlier part of this year, we ended into a period of new stress, basically Russia invading Ukraine. And it's interesting to see what happened to credit spreads during that time frame. So on a year to date basis, what you basically saw was double B's were underperforming because the Fed was raising rates. At the same time, credit risk was actually outperforming single B's and triple C's on a relative basis to double B's. But come April of 2022, they actually started to reverse, and you saw double B's start to outperform. And there was an indication that credit stress might actually be more of a concern on people's minds. And so you actually saw single B's and triple C's begin to underperform on a relative basis to double B's. What we are seeing in the credit markets today is, you know, something that we hadn't seen in a number of decades in the past. You know, when we think about what's going on in the environment right now, we came into the beginning of the year where inflation started to increase. And then with Russia, Russia invading Ukraine, basically that kind of added a spark to kind of really set the fire on inflation. And now we're sitting it roughly at 9% year over year inflation rate. We haven't really seen this type of inflation environment for upwards of four decades. So when you think about the investing world, there are not that many participants in the markets today that have actually directly experienced what we are experiencing now or are likely to experience if inflation stays at very high levels for the foreseeable future. Now, when we think about inflation, basically we were concerned about the inflationary environment going into the beginning of this year. So we really pulled back on our exposure to duration, longer duration assets and have benefited, because of that. Now we do not believe that we are going to run rate at a 9% inflation rate. You're already starting to see a lot of your data points tick over, but do not believe that we're going back to this one to 2% inflation rate environment.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512